|Artur Kwaśniewski, Maryla Krasnowska, Beata Korbuszewska-Gontarz|
Low molecular weight heparin (nadroparin) in nebulization as an additional treatment was applied in 11 patients with bronchial asthma and chronic obstructive pulmonary disease as well as in 10 healthy controls. Heparin was nebulized twice a day, 15 kU per dose. At the beginning of the study and after 3 and 6 days of heparin treatment several parameters of the blood clotting were estimated both in treated and non-treated groups (e.g., APTT, fibrinogen, platelets, anti-Xa activity). Similar parameters were measured after 7, 8 and 9 days, although heparin was no longer administered at that time. Nadroparin increased serum anti-Xa activity in all subjects. This change was less pronounced in asthmatics, but tended to last longer than in controls (p<0.05). No changes in other estimated parameters were observed.
Alergia Astma Immunol 2000; 5(2): 123-127
keywords: heparyna drobnocząsteczkowa w inhalacji, układ krzepnięcia, astma oskrzelowa, LMWHeparin inhalation, blood clotting, bronchial asthma
pages: from 123 to 127
|estimated time of download (75 kB)|